0888-8809/08/$15.00/0 Printed in U.S.A.
Molecular Endocrinology 22(7):1509–1520 Copyright © 2008 by The Endocrine Society doi: 10.1210/me.2007-0519
MINIREVIEW
Nuclear Hormone Receptors for Heme: REV-ERB␣ and REV-ERB Are Ligand-Regulated Components of the Mammalian Clock Thomas P. Burris Nuclear Receptor Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 70808 The nuclear hormone receptors (NHRs), REVERB␣ and REV-ERB, regulate a number of physiological functions including the circadian rhythm, lipid metabolism, and cellular differentiation. These two receptors lack the activation function-2 region that is associated with the ability of NHRs to recruit coactivators and activate target gene transcription. These NHRs have been characterized as constitutive repressors of transcription due to their lack of an identified ligand and their strong ability to recruit the corepressor, nuclear receptor corepressor. Recently, the porphyrin heme was demonstrated to function as a ligand for both REV-
ERBs. Heme binds directly to the ligand-binding domain and regulates the ability of these NHRs to recruit nuclear receptor corepressor to target gene promoters. This review focuses on the physiological roles that these two receptors play and the implications of heme functioning as their ligand. The prospect that these NHRs, now known to be regulated by small molecule ligands, may be targets for development of drugs for treatment of diseases associated with aberrant circadian rhythms including metabolic and psychiatric disorders as well as cancer is also addressed. (Molecular Endocrinology 22: 1509–1520, 2008)
N
the NHRs have identified ligands in which the receptors clearly function as ligand-activated transcription factors whereby, small hydrophobic molecules, such as steroid hormones, fatty acids, lipophilic vitamin derivatives, and dietary metabolites, act as ligands for the NHR proteins binding within the LBD. The remaining half of the human receptor superfamily and nearly all of the Drosophila and Caenorrhabitis elegans NHRs are orphan receptors, so called due to the lack of an identified ligand. NHRs bind directly to specific DNA sequences within the genome near their cognate target genes and regulate the rate of transcription in a ligand-dependent manner. Most bind to DNA as dimers: either homodimers (as is the case for steroid receptors) or heterodimers with another member of the NHR superfamily, the retinoid X receptor (2, 3). A limited number of NHRs have the ability to bind to DNA as monomers. Ligand binding (agonist) induces a conformational change within the LBD that allows for a unique surface to be created that is recognized by a class of proteins known as coactivators (4). Once the coactivator proteins are recruited to the NHR LBD, and hence the promoter region of the gene, the rate of mRNA synthesis is increased due to stabilization of the preinitiation complex and modification of the chromatin structure (5). Whereas most of the NHRs behave in this manner, others may exhibit constitutive activity due to some degree of constant binding to coactivator pro-
UCLEAR HORMONE RECEPTORS (NHRs) are transcription factors that regulate a wide range of biological processes including carboyhydrate and lipid metabolism, cellular proliferation and differentiation, reproductive system development and function, and circadian rhythms. NHRs have a conserved domain structure with a variable amino-terminal domain (A/B region) and highly conserved DNA-binding domain (C region), a hinge region (D region), and a carboxy-terminal ligandbinding domain (E region, or LBD) (Fig. 1) (1). A small number of receptors also contain an F region that has unclear function. Forty-eight members of the NHR superfamily exist in humans, approximately half that number exist in Drosophila, and six times that number are found in the nematode. In humans, approximately half of First Published Online January 24, 2008 Abbreviations: ALAS, Aminolevulinic acid synthase; apoCIII, apolipoprotein CIII; BMAL1, brain and muscle Arnt-like protein 1; LBD, ligand-binding domain; NCoR, nuclear receptor corepressor; NHR, nuclear hormone receptor; NPAS2, neuronal PAS domain protein 2; PGC, PPAR coactivator; PPAR, peroxisome proliferator-activated receptor; Rev RE, REV-ERB response element; ROR, retinoic acid receptorrelated orphan receptor; RORE, ROR response element; VLDL, very-low-density lipoprotein. Molecular Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.
1509
1510 Mol Endocrinol, July 2008, 22(7):1509–1520
Burris • Minireview
Fig. 1. Comparison of the Orphan NHRs, REV-ERB␣ and REV-ERB, to the Drosophila melanogaster E-75 DBD, DNA-binding domain. Numbers indicate amino acids. Letters A–F refer to the domain structure common to most NHRs as described in the text. dE75, Drosophila melanogaster E-75.
teins or exhibit transcriptional silencing (active repression) of gene transcription due to constitutive binding of corepressor proteins that mediate recruitment of histone deacetylases (6). The wide range of physiological and pathological process regulated by NHRs has made this superfamily of receptors a rich source of targets for drug development. The steroid receptors, including the mineralocorticoid, estrogen, androgen, glucocorticoid, and progesterone receptors, have been successful targets for a range of diseases including cardiovascular disorders, cancer, and inflammation. The thyroid hormone, peroxisome proliferator-activated, and retinoic acid and retinoid X receptors have been successful target for development of drugs for metabolic and skin disorders as well as cancer. In addition, peroxisome proliferator-activated receptor (PPAR)␣ and PPAR␥ are targets for the fibrates and thiazolidienedione classes of drugs used to treat dyslipidemia and type 2 diabetes mellitus, respectively. Recently deorphanized receptors such as the liver X receptors ␣ and  [NR1H3 and NR1H2] and farnesoid X receptor (NR1H4) hold great promise for development of additional drugs targeting metabolic diseases (7, 8). Additional deorphanization efforts will likely yield an even greater number of targets for drug discovery as well as characterization of novel physiological regulatory processes.
REV-ERB␣ AND REV-ERB, UNUSUAL MEMBERS OF THE NHR SUPERFAMILY REV-ERB␣ and REV-ERB are two unique orphan members of the NHR superfamily. REV-ERB␣ is encoded by the opposite DNA strand of the c-erbA oncogene, which is the thyroid hormone receptor-␣ (9–11). Both REV-ERB␣ and the closely related REVERB that was identified a few years later have an atypical LBD in which the carboxy-terminal activation function-2 is missing (Fig. 1) (12–14, 107). This region of the LBD forms helix 12 and is required for recognition of coactivators required for transcriptional activation by NHRs (4). Consistent with the lack of the activation function-2 region, both of these NHRs have been demonstrated to be to be constitutive repressors of transcription due to their inability to bind to coacti-
vators and their constant binding corepressors such as nuclear receptor corepressor (NCoR) (15). These two NHRs display an overlapping pattern of expression both spatially and temporally. Expression is exceptionally high in the liver, adipose tissue, skeletal muscle, and brain, and both exhibit circadian patterns of expression (16–19). REV-ERB␣ and REV-ERB recognize two classes of DNA response elements and can bind to DNA as either monomers or homodimers, depending on the nature of the response element. REV-ERBs bind as a monomer to a (A/G)GGTCA halfsite with a 5⬘ AT-rich extension or as a homodimer to a direct repeat 2 element (AGGTCA sequence with a 2-bp spacer) (20, 21). When bound to their response element [REV-ERB response element (RevRE)] within the promoter of a target gene, the REV-ERBs constitutively recruit corepressors to the promoter, resulting in repression of the target gene due to active histone deacetylation and condensation of the chromatin (15, 21). Another orphan NHR subclass known as the retinoic acid receptor-related orphan receptor [ROR (␣,, and ␥); NR1F1, NR1F2, and NR1F3] also recognize at least a subset of RevREs and are often coexpressed in the same tissues as the REV-ERBs (22). In contrast to the REV-ERBs, the RORs are constitutive activators of transcription. Thus, the balance of expression of ROR (activator) vs. REV-ERB (repressor) has been suggested to be critical for dynamic regulation of target genes containing these elements. An interesting feedback loop also exists between these two NHRs. The Rev-erb␣ promoter contains a RevRE and is thus responsive to both autoregulation and regulation ROR␣ (23–25). Additionally, expression of a dominant-negative form of REV-ERB in C2C12 myocytes results in an approximate 6-fold increase in ROR␣ expression indicating that REV-ERB represses expression of ROR␣ and thus completes the regulatory loop (26). Both REV-ERBs and ROR␣♦ share a number of common target genes indicating that they likely coordinately regulate physiological processes.
REV-ERBs AND REGULATION OF METABOLISM Loss of function experiments provide unequivocal data illustrating a role for REV-ERBs in lipid metabolism. Rev-erb␣⫺/⫺ mice exhibit a dyslipidemic pheno-
Burris • Minireview
Mol Endocrinol, July 2008, 22(7):1509–1520 1511
type with elevated very-low-density lipoprotein (VLDL) triglyceride levels along with increased liver and serum apolipoprotein CIII (apoCIII) expression (Table 1) (27, 28). apoCIII is a component of both highdensity lipoprotein and VLDL and plays a role in regulation of lipoprotein lipase activity and triglyceride levels. The staggerer (sg/sg) mouse, which harbors a ROR␣ loss of function mutation, displays reduced apoCIII expression as well as lowered triglyceride levels (28). These results are consistent with the in vitro observations that apoCIII is a direct target gene of these NHRs and is repressed by REV-ERB␣ and activated by ROR␣ (both in human and rodent cell lines) (27, 28). Apoliprotein AI, a component of high-density lipoprotein, is also regulated by both REV-ERB␣ and ROR␣; however, this appears to be species specific and does not occur in human cell lines (29). Recently, additional REV-ERB␣ target genes, including ElovI3 and plasminogen activator inhibitor type I (PAI-1), have been identified, further solidifying its role in lipid metabolism and atherosclerosis (30, 31). ElovI3 encodes a very long-chain fatty acid elongase found in the liver and adipose tissue whereas PAI-1 is a regulator of the fibrinolytic system and is believed to play a role in atherogenesis. Additional loss of function experiments in which a dominant-negative form of REV-ERB (lacking its LBD and thus unable to repress transcription) was expressed in mouse myogeneic C2C12 cells provides additional insight into the role of REV-ERBs in lipid metabolism (26). This study first demonstrated that REV-ERB was expressed in proliferating myoblasts and decreased 2- to 3-fold as the cells exit the cell cycle and form differentiated multinucleated myotubes. Cells expressing the dominant-negative form of REV-ERB exhibit decreases in expression of critical genes involved in lipid metabolism including Fat/ CD36, Fabp-3, Fabp-4, Ucp3, Srebp-1c, and Scd-1. Although it is not clear whether REV-ERB directly regulates these genes, it clearly demonstrates a role for REV-ERB regulating genes (at least indirectly) that are involved in fatty acid and lipid absorption, energy expenditure, and lipogenesis in muscle. Consistent with the observation that REV-ERBs inhibit myogenesis (32, 33), the expression myostatin (a growth factor that limits muscle tissue growth) was reduced approximately 24-fold in the C2C12 cells overexpressing the
dominant-negative REV-ERB (26). Interestingly, mice deficient in myostatin have reduced accumulation of body fat, increased muscle mass, and increased insulin sensitivity (34), and Scd-1⫺/⫺ mice have increased insulin sensitivity and reduced VLDL and triglyceride levels and are resistant to diet-induced obesity (35, 36). In contrast to the role of REV-ERBs inhibiting myogenesis, these NHRs are involved in induction of adipogenesis. Chawla and Lazar (37) first demonstrated that Rev-erb␣ was highly induced during adipogenesis. A PPAR response element has been found in the promoter of the Rev-erb␣ gene (38) and the role of REV-ERB␣ in adipogenesis may be linked to PPAR␥, which is also induced during adipogenesis (39). This Rev-erb␣ PPAR response element is also responsive to PPAR␣, which is particularly interesting given the role of PPAR␣ in regulation of Bmal1 expression and regulation of the circadian rhythm in the liver (40). PPAR␥ agonists increase Rev-erb␣ expression in adipose tissue both in vivo and in 3T3-L1 preadipocytes as do PPAR␣ agonists in hepatocytes (38, 39). Overexpression of REV-ERB␣ in 3T3-L1 preadipocytes results in increased expression of markers of adipogenesis including aP2, PPAR␥, and CCAAT enhancer binding protein-␣ along with small increase in lipid accumulation (39). Furthermore, overexpression of REV-ERB␣ in these cells synergized with the PPAR␥ ligand rosiglitazone to increase these markers of adipogenesis (39). Although the Rev-erb␣⫺/⫺ mice do not exhibit an overt adipose or muscle phenotype (41), the mice do display alterations in lipid metabolism as discussed above and, in addition, exhibit alterations in myosin heavy chain isoform expression in skeletal muscle (42). Functional redundancy between REVERB␣ and REV-ERB may be one explanation for the limited phenotype. Development of Rev-erb null mice as well as double-knockout mice will be needed to address this issue in the future.
REV-ERBs AND THE MAMMALIAN CLOCK Circadian rhythms play an essential role in aspects of physiology and behavior including the sleep-wake cy-
Table 1. Metabolic Phenotypes of Mice Harboring Mutations in the Genes of the Circadian Oscillator Mice
Phenotype ⫺/⫺
Rev-erb␣
Bmal1⫺/⫺
1Triglcyerides 1VLDL 1apoCIII 220% Body weight 2Gluconeogenesis 2Life span Progeria-like phenotype Impaired adipogenesis (in null embryonic fibroblasts)
Mice sg/sg
Rora
Clockmut
Phenotype
1VLDL 2apoAI 2HDL Susceptible to atherosclerosis Obesity 1Cholesterol 1Glucose 1Triglycerides 2Insulin
1512 Mol Endocrinol, July 2008, 22(7):1509–1520
cle, feeding, metabolism, body temperature, blood pressure, and renal function. The circadian rhythm is generated by feedback loops in gene expression in which heterodimers of brain and muscle Arnt-like protein 1 (BMAL1) and circadian locomoter output cycles kaput (CLOCK) induce the expression of the Cryptochrome (Cry1, Cry2) and Period (Per1, Per2, Per3) genes (Fig. 2). As CRY and PER reach critical levels, they are able to repress the stimulatory effect of the CLOCK/BMAL1 dimer on the expression of their own genes. REV-ERB␣ has been demonstrated to be the major regulator of the cyclic expression of Bmal1 (18, 43). Two ROR response elements (ROREs)/RevREs are located in the Bmal1 promoter, and Bmal1 transcription is repressed by REV-ERB␣. REV-ERB␣ expression is, in turn, regulated by the BMAL1/CLOCK heterodimers via E-boxes found within the Rev-erb␣ promoter (44, 45). Rev-erb⫺/⫺ mice exhibit aberrant expression of Bmal1 and display alterations in the period and phase of their circadian behavior patterns (43). The RORs have also been demonstrated to play a key role in regulation of Bmal1 via the identical RORE/RevRE, and consistent with this observation the staggerer mice display alterations in the circadian oscillator (46). When this element responsive to both REV-ERBs and RORs is placed upstream of a reporter con-
Burris • Minireview
struct, this element alone is enough to drive the circadian expression of the reporter gene (47). This is consistent with the observation that REV-ERB␣ (the repressor) and ROR␣ (the activator) are expressed in an oscillatory fashion 180° out of phase with one another (43, 46) (Fig. 2). Interestingly, the REV-ERB target gene, Bmal1, which is such a critical component of the circadian oscillator, is also essential for adipogenesis (48).
The DROSOPHILIA MELANOGASTER NHR, E-75, HEME, AND REV-ERBs A Drosophila ortholog of human REV-ERB␣, E75, was recently demonstrated to contain a heme prosthetic group (49). The heme is apparently tightly bound, and removal of the heme is associated with loss of E75 stability. The oxidation state of heme within E75 determines whether this NHR can interact with its heterodimer partner, DHR3 and, interestingly, this dimer interaction is regulated by binding of either NO or CO to the heme sensor, indicating that E75 may function as a diatomic gas sensor (49). Coordination of heme was assessed by site-directed mutagenesis in this study (49) and well as in a more recent study (50). E75
Fig. 2. Mechanism of the Cellular Circadian Oscillator The top portion of the figure illustrates the oscillations in Bmal1/Clock and Per/Cry and ROR␣/REV-ERB␣ during the 24-h cycle. The lower portion of the figure illustrates the molecular mechanism responsible for creation of the oscillation. The roles of NHRs, ROR␣, and REV-ERB␣ are highlighted in this figure.
Burris • Minireview
functions in Drosophila development and a number of potential roles for heme were proposed for regulation of E75 activity including regulation of stability of the protein, a redox sensor, and a sensor of diatomic gases (49). The closest human NHR relatives of Drosophila E75 are REV-ERB ␣ and REV-ERB  (Fig. 1). Alignment of the LBDs of the receptors reveals conservation of several residues that have been demonstrated to be important for coordination of heme (49, 50). Thus, it becomes conceivable that the REV-ERBs may also bind to heme. REV-ERBs ARE HEME RECEPTORS Recent work from our laboratory (in collaboration with Fraydoon Rastinejad) as well as that from the Lazar group demonstrated that heme is the ligand for REV-ERB␣ (51, 52) and REV-ERB (51). However, unlike the Drosophila E-75 in which heme is essential for the stability of the protein, the REVERBs appear to function as true receptors for heme and alter their function in response to changing intracellular heme concentrations. Both groups demonstrated that heme binds reversibly and specifically to the LBD of REV-ERB and modulates the ability of the receptor to recruit the corepressor NCoR (51, 52). Based on isothermal titration calorimetry, the affinity of heme for REV-ERB␣ and REVERB is approximately 2–4 M (51). Heme binding is required for efficient NCoR recruitment, and mutations that eliminate the ability of the receptor to bind heme also eliminate its ability to recruit NCoR. Alterations in intracellular heme levels also modulate the expression of REV-ERB target genes such as Bmal1 and Elovl3 in a manner consistent with heme stabilizing the REV-ERB-NCoR interaction. Diatomic gasses such as nitric oxide did not appear to mod-
Mol Endocrinol, July 2008, 22(7):1509–1520 1513
ulate REV-ERB activity. A model for ligand regulation of REV-ERB activity is shown in Fig. 3. Although the idea that heme is a ligand for a NHR may seem peculiar, a closer look reveals that this is not at all an unusual situation. In terms of molecular weight, although heme is at the high end of the range of sizes of NHR ligands, it is clearly not the largest (Fig. 4). T3, a thyroid hormone receptor ligand, as well as ligands for pregnane X receptor such as rifampacin, are larger. Certainly the hydrophobic character of heme is consistent with the characteristics commonly associated with NHR ligands. A recent study reported the crystal structure of the REV-ERB LBD indicating that the ligand-binding pocket is too small to accommodate any ligands of the size characteristic of nuclear receptor ligands (53). The receptor used by these investigators lacked helices 1 and 2 as well as a long amino acid insert between helices 2 and 3 that is characteristic of REV-ERBs; thus, this structure may not represent the physiologically relevant structure. The discovery of heme as a ligand for the REV-ERBs also has implications with respect to our understanding of how NHRs typically function. In the classical model for NHR action, the receptor is inactive, and upon ligand binding the receptor undergoes a conformational change allowing recruitment of coactivators, thus becoming an activator of transcription. The REV-ERBs were previously believed to lack ligands and function as constitutive repressors of gene transcription. However, these two studies have demonstrated a new model in which binding of a physiological ligand transforms an inactive receptor into one that efficiently recruits corepressor and is a repressor of transcription (51, 52). Given that there are other members of the NHR superfamily that are thought to be constitutive repressors of tran-
Fig. 3. Model Illustrating the Proposed Mechanism for Heme Modulation of REV-ERB Activity REV-ERB functions as a receptor for heme. REV-ERB recognizes and binds specific DNA sequences known as RevREs in the promoter regions of its target genes. Heme binds directly to the LBD of REV-ERB and increases the affinity of the receptor for the corepressor NCoR. When NCoR is recruited to the promoter by REV-ERB, the gene is repressed due to the histone deacetylase activity that is associated with the NCoR/histone deacetylase complex. Modulation of REV-ERB target genes is associated with regulation of physiological functions such as lipid metabolism, circadian rhythm and cellular differentiation. DBD, DNA-binding domain.
1514
Mol Endocrinol, July 2008, 22(7):1509–1520
Burris • Minireview
Fig. 4. Examples of Ligands for NHRs Heme is a ligand for REV-ERB␣ and REV-ERB, T3 is a ligand for the thyroid hormone receptor, 1,25-dihydroxyvitamin D3 is a ligand for the vitamin D receptor, estradiol is a ligand for the estrogen receptor ␣ and , chenodeoxycholic acid is a ligand for farnesoid X receptor, and rifampicin is a ligand for pregnane X receptor. MW, Molecular weight.
scription, such as the chicken ovalbumin upstream promoter-transcription factors, the example of the REVERBs may not be unique.
REGULATION OF HEME SYNTHESIS Like the REV-ERBs, the synthesis of heme has been directly correlated to the circadian rhythm via regulation of the expression of the rate-limiting enzyme in heme synthesis, aminolevulinic acid synthase (ALAS) (54–56) (Fig. 5). Approximately 15% of heme synthesis occurs in the liver where heme is incorporated into a number of metabolic enzymes (e.g. p450s), whereas most of the remaining 85% is synthesized in erythroid progenitors for incorporation primarily into hemoglobin (57). Heme synthesis occurs both in the cytosolic and mitochondrial compartments in both systems; however, liver vs. erythroid regulation of synthesis exhibits major differences. In the erythroid cells heme synthesis is regulated primarily by the availability of iron, whereas in the liver, heme biosynthetic enzymes are subject to rapid turnover and are able to respond to the changing metabolic environment (57). The rate-
limiting step in heme synthesis is catalyzed by two distinct ALAS enzymes, ALAS1 and ALAS2. ALAS1 is ubiquitously expressed whereas ALAS2 is expressed only in erythroid progenitors. Distinctions between the regulation of ALAS1 and ALAS2 provide for the observed differences in regulation of heme synthesis in the liver vs. the erythroid cells. Interestingly, when Reverb was first described, it was isolated in chickens and was found to be highly expressed in the spleen, which is the major organ of erythropoesis in birds (14). Given the proximity of Rev-erb expression, heme synthesis, and erythropoesis in this tissue, it is important to investigate the potential role of Rev-erb in erythropoesis. HEME AS A REV-ERB LIGAND REGULATING THE CIRCADIAN RHYTHM Alas1 expression is regulated in a circadian fashion and is dependent on the PER1 and PER2 components of the clock (56). Additionally, components of the cellular circadian clock such as neuronal PAS domain protein 2 (NPAS2), a homolog of CLOCK expressed in the forebrain, which also functions as a heterodimer with BMAL1, and PER2 contain heme as a prosthetic group (54, 58). NPAS2 activity has been shown to be
Burris • Minireview
Mol Endocrinol, July 2008, 22(7):1509–1520 1515
Fig. 5. Schematic Illustration the Pathway Responsible for Biosynthesis of Heme, the Ligand for REV-ERB␣ and REV-ERB CoA, Coenzyme A.
a gas-sensitive transcription factor (58), and the NPAS2/BMAL1, along with PER, is an essential regulator of Alas1 expression (54, 56), leading to the hypothesis that heme may play a role in circadian feedback loop whereby it regulates the activity of critical clock components and they, in turn, regulate heme synthesis. Consistent with this hypothesis was the observation that injection of heme into mice altered mPer1 and mPer2 expression and modified circadian locomotor behavior relative to injection of vehicle alone (54). Both the NPAS2/BMAL1 and CLOCK/BMAL1 heterodimers are sensitive to the redox state of nicotinamide adenine dinucleotide and may utilize this mechanism to allow the entrainment of the circadian clock to the nutritional state (59). Feeding clearly has the ability to entrain the circadian clock, particularly in the liver where metabolism of carbohydrates and lipids are coordinated; interestingly, this occurs in the absence of input from the central circadian oscillator in the suprachiasmatic nucleus of the brain (60–62). A link between the circadian rhythm and glucose/lipid metabolism has been recognized for some time. Plasma glucose and triglyceride levels display a circadian pattern in addition to circulating levels of hormone involved in glucose and lipid me-
tabolism including corticosterone and adiponectin (63). This link between the circadian rhythm and metabolic disorders is clearly demonstrated in mice deficient in either Bmal1 or harboring a mutant Clock gene (Table 1). These mice display abnormalities similar to metabolic syndrome including obesity, dyslipidemia, and impaired glucose metabolism (63, 64). A heme-nutritional status relationship was revealed during the analysis methods of treatment for genetic diseases associated with accumulation of heme precursors, porphyrias. The effects of accumulation of heme precursors lead to mental disturbances and can be precipitated by fasting. Glucose infusion is the typical treatment of choice during a porphyric attack, but the exact mechanism of action was not understood until recently. Handschin et al. (65) found that the nuclear receptor coactivator, PPAR coactivator (PGC)-1␣, directly regulates the expression of Alas1, and hence heme synthesis. The expression of PGC-1␣ is significantly up-regulated in response to fasting and mediates the transition toward oxidation of fatty acids and gluconeogenesis when plasma glucose is low (66). Glucose infusion results in decreased expression of PGC-1␣ and thus, a decrease in expression of Alas1 and de-
1516 Mol Endocrinol, July 2008, 22(7):1509–1520
creased heme synthesis, which results in decreased accumulation of heme precursors in the porphyric individual. This analysis of the role of PGC-1␣ in regulation of heme synthesis provides significant insight into how heme is providing a signal as to the nutritional status of the organism. Because heme production is coupled to PGC-1␣ expression, there is a clear link between nutritional status and heme; therefore, heme may provide a key connection as a signaling molecule to indicate the nutritional status to the circadian oscillatory machinery and allow it to respond appropriately. Normal operation of the circadian oscillator is required for normal metabolic regulation, and dysregulation is associated with a metabolic disease phenotype. Additionally, methods to modify the activity of various components of the oscillator, such as the REV-ERBs, may be useful for treatment of metabolic diseases.
HEME AS A REV-ERB LIGAND REGULATING DIFFERENTIATION Because the REV-ERBs play a role in both adipogenesis and myogenesis, this brings about the question of what role heme may be playing as a regulator of REV-ERB function in these processes. Heme is a porphyrin that is an essential prosthetic group for several proteins critical for skeletal muscle function including myoglobin and cytochrome oxidase. Heme serves not only a functional role as a prosthetic group within proteins but also as an independent regulatory role by which it increases myoglobin expression and mitochondrial biogenesis (67–69). Heme has also been shown to induce differentiation and maturation of rat primary skeletal muscle cells as well as increase their aerobic capacity (70, 71). Interestingly, the expression and activity of ALAS1 in muscle is increased by exercise (68, 69, 72–74). This suggests that one adaptive response of skeletal muscle in response to exercise will be an increase in intracellular heme levels, which correlates with increased differentiation/maturation and mitochondrial biogenesis (aerobic capacity). It is possible that this increase in heme synthesis may be mediated by the exercise-induced increase in PGC-1␣ expression (65, 75, 76). Thus, it is clear that intracellular heme levels vary under differing physiological conditions in muscle and may affect the activity of the REV-ERBs. Heme has also been demonstrated to play an important role in adipogenesis. If heme biosynthesis is blocked using pharmacological methods, 3T3-L1 cells fail to differentiate into adipocytes whereas addition of heme induces adipogenesis (77). The role that REV-ERB plays in mediating these effects of heme is unclear currently; however, evidence suggests that these recently deorphanized NHRs may be playing an important role.
Burris • Minireview
LIGANDS FOR REV-ERBs: IMPLICATIONS FOR DISEASES ASSOCIATED WITH CIRCADIAN RHYTHM DYSFUNCTION Aberrant circadian rhythms are associated with numerous disorders in the human. Sleep disorders including chronic insomnia are clearly associated with an abnormal circadian rhythm (78, 79). Mutations or polymorphisms in either key components of the mammalian clock mechanism or genes that directly regulate the stability of the components of the mechanisms affect the sleep-wake cycle (80, 81). Mood disorders in humans, such as bipolar disorder, major depressive disorder, and seasonal affective disorder, have been demonstrated to be associated with alterations in the circadian rhythm (82, 83). Mutations in the Clock gene in mice induce mania-like behavior (84), and polymorphisms in the human Clock and Bmal1 genes are associated with bipolar disorder (85–89). Mood-stabilizing drugs such as lithium and valproate have been demonstrated to have direct effects on circadian clock. Lithium, which lengthens the circadian period in numerous organisms, including humans (90), has been recently shown to affect the pattern of Bmal1 expression by modulation of REV-ERB␣ stability (91). Valproate alters the level of expression of several circadian genes in the brain (92) as does the selective serotonin reuptake inhibitor antidepressant fluoxitene (93). In addition to clear linkage of the circadian clock to psychiatric disorders, the circadian rhythm plays an essential role in regulation of metabolism as previously discussed. However, in addition to the experimental genetic evidence linking the circadian rhythm to metabolic regulation, there are considerable epidemiological studies pointing to a clear role of the clock in metabolic disease. Several studies have shown that the incidence of cardiovascular disease and metabolic disturbances is higher in individuals who alter their normal sleep-wake pattern for shift work (94–96). Epidemiological as well as biochemical data have also shown a relationship between abnormal circadian rhythms and cancer (97–99). Two independent studies have shown that women shift workers, who are required to reverse their sleep-wake cycle, have as much as a 60% increase in the risk of developing breast cancer (100, 101). Consistent with the observation of a link between circadian regulation and cancer, Fu et al. (102) showed that mice deficient in Per2 expression were prone to development of cancer and suggested that PER2 is a tumor suppressor. Interestingly, Per genes have been shown to be deregulated in up to 95% of human breast cancers (103). Additionally, Matsuo et al. (104) demonstrated a direct regulatory link between the circadian rhythm and cell cycle where wee1, a critical cell cycle regulator, was directly regulated by components of the circadian oscillator. Previous studies have also shown that REV-ERB␣ regulates the expression of the c-myc protooncogene (105). Thus, there is clear evidence that alterations in
Burris • Minireview
the normal circadian rhythm are associated with human disease.
CONCLUSIONS The discovery that the orphan NHRs, REV-ERB␣ and REV-ERB, are receptors for heme opens many new areas of investigation. From the physiological perspective, this observation has solidified a recently observed link demonstrating close association between regulation of the circadian rhythm and metabolic function. Additionally, previous studies demonstrating circadian oscillations in the expression of heme synthetic enzymes appear to bear additional significance now. We have recently observed that intracellular heme levels oscillate in a circadian fashion in synchronized NIH3T3 cells (106). The fact that the REV-ERBs are receptors for heme suggests that heme is likely to play an important role in regulation of functions that have been associated with REV-ERB including circadian function, glucose and lipid metabolism, adipogenesis, and myogenesis. Because these NHRs regulate such a critical physiological function, the circadian rhythm, the prospect that synthetic REV-ERB ligands can be designed treat disorders associated with aberrant circadian function, such as metabolic and psychiatric diseases and cancer, is certainly a possibility. It is also possible that short acting synthetic REV-ERB ligands may be useful for entrainment or resetting the circadian clock and thus be useful for sleep disorders and/or jet lag. Acknowledgments Received November 19, 2007. Accepted January 17, 2008. Address all correspondence and requests for reprints to: Dr. Thomas Burris, Nuclear Receptor Biology Laboratory, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 70808. E-mail:
[email protected]. Disclosure Statement: T.P.B. was previously employed by and has equity interest in Eli Lilly & Co. T.P.B. consults for PheneX Pharmaceuticals AG, Invitrogen Inc, GTx, Inc., and Orphagen Inc.
REFERENCES 1. Savkur RS, Bramlett KS, Clawson D, Burris TP 2004 Pharmacology of nuclear receptor-coregulator recognition. In: Vitamins and hormones. Vol 68. San Diego: Elsevier Academic Press; 145–183 2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily—the 2nd decade. Cell 83:835–839 3. Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841–850 4. Savkur RS, Burris TP 2004 The coactivator LXXLL nuclear receptor recognition motif. J Peptide Res 63: 207–212
Mol Endocrinol, July 2008, 22(7):1509–1520 1517
5. Lonard DM, O’Malley BW 2007 Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 27:691–700 6. Giguere V 1999 Orphan nuclear receptors: from gene to function. Endocr Rev 20:689–725 7. Michael LF, Schkeryantz JM, Burris TP 2005 The pharmacology of LXR. Mini-Reviews Medicinal Chem 5:729–740 8. Cariou B, Staels B 2007 FXR: a promising target for the metabolic syndrome? Trends Pharmacol Sci 28:236–243 9. Lazar MA, Hodin RA, Darling DS, Chin WW 1989 A novel member of the thyroid steroid-hormone receptor family is encoded by the opposite strand of the rat C-ERBA-␣ transcriptional unit. Mol Cell Biol 9:1128–1136 10. Miyajima N, Horiuchi R, Shibuya Y, Fukushige S, Matsubara K, Toyoshima K, Yamamoto T 1989 2 ERBa homologs encoding proteins with different T3 binding-capacities are transcribed from opposite DNA strands of the same genetic-locus. Cell 57: 31–39 11. Miyajima N, Kadowaki Y, Fukushige S, Shimizu S, Semba K, Yamanashi Y, Matsubara K, Toyoshima K, Yamamoto T 1988 Identification of 2 novel Members of ERBa superfamily by molecular-cloning—the geneproducts of the 2 are highly related to each other. Nucleic Acids Res 16:11057–11074 12. Dumas B, Harding HP, Choi HS, Lehmann KA, Chung M, Lazar MA, Moore DD 1994 A new orphan member of the nuclear hormone-receptor superfamily closely-related to REV-ERB. Mol Endocrinol 8:996–1005 13. Forman BM, Chen J, Blumberg B, Kliewer SA, Henshaw R, Ong ES, Evans RM 1994 Cross-talk among ROR-␣-1 and the REV-ERB family of orphan nuclear receptors. Mol Endocrinol 8:1253–1261 14. Bonnelye E, Vanacker JM, Desbiens X, Begue A, Stehelin D, Laudet V 1994 REV-ERB-, a new member of the nuclear receptor superfamily, is expressed in the nervoussystem during chicken development. Cell Growth Differ 5:1357–1365 15. Yin L, Lazar MA 2005 The orphan nuclear receptor REV-ERB ␣ recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. Mol Endocrinol 19:1452–1459 16. Zvonic S, Ptitsyn AA, Conrad SA, Scott LK, Floyd ZE, Kilroy G, Wu XY, Goh BC, Mynatt RL, Gimble JM 2006 Characterization of peripheral circadian clocks in adipose tissues. Diabetes 55:962–970 17. Balsalobre A, Damiola F, Schibler U 1998 A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 93:929–937 18. Guillaumond F, Dardente H, Giguere V, Cermakian N 2005 Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms 20:391–403 19. Torra IP, Tsibulsky V, Delaunay F, Saladin R, Laudet V, Fruchart JC, Kosykh V, Staels B 2000 Circadian and glucocorticoid regulation of Rev-erb ␣ expression in liver. Endocrinology 141:3799–3806 20. Harding HP, Lazar MA 1993 The orphan receptor REVERBA-␣ activates transcription via a novel response element. Mol Cell Biol 13:3113–3121 21. Harding HP, Lazar MA 1995 The monomer-binding orphan receptor REV-ERB represses transcription as a dimer on a novel direct repeat. Mol Cell Biol [Erratum (1995) 15:6479] 15:4791–4802 22. Smith AG, Muscat GEO 2006 Orphan nuclear receptors: therapeutic opportunities in skeletal muscle. Am J Physiol Cell Physiol 291:C203–C217 23. Adelmant G, Begue A, Stehelin D, Laudet V 1996 A functional Rev-erb ␣ responsive element located in the human Rev-erb ␣ promoter mediates a repressing activity. Proc Natl Acad Sci USA 93:3553–3558
1518 Mol Endocrinol, July 2008, 22(7):1509–1520
24. Delerive P, Chin WW, Suen CS 2002 Identification of Rev-erb ␣ as a novel ROR ␣ target gene. J Biol Chem 277:35013–35018 25. Raspe E, Mautino G, Duval C, Fontaine C, Duez H, Barbier O, Monte D, Fruchart J, Fruchart JC, Staels B 2002 Transcriptional regulation of human Rev-erb ␣ gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor ␣. J Biol Chem 277: 49275–49281 26. Ramakrishnan SN, Lau P, Burke LJ, Muscat GEO 2005 Rev-erb  regulates the expression of genes involved in lipid absorption in skeletal muscle cells—evidence for cross-talk between orphan nuclear receptors and myokines. J Biol Chem 280:8651–8659 27. Raspe E, Duez H, Mansen A, Fontaine C, Fievet C, Fruchart JC, Vennstrom B, Staels B 2002 Identification of Rev-erb ␣ as a physiological repressor of apoC-III gene transcription. J Lipid Res 43:2172–2179 28. Raspe E, Mautino G, Duez H, Fruchart JC, Staels B 2002 Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor Reverb ␣. J Biol Chem 277:49275–49281 29. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, Staels B 1998 The nuclear receptors peroxisome proliferator-activated receptor ␣ and Rev-erb ␣ mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273:25713–25720 30. Anzulovich A, Mir A, Brewer M, Ferreyra G, Vinson C, Baler R 2006 Elovl3: a model gene to dissect homeostatic links between the circadian clock and nutritional status. J Lipid Res 47:2690–2700 31. Wang J, Yin L, Lazar MA 2006 The orphan nuclear receptor Rev-erb ␣ regulates circadian expression of plasminogen activator inhibitor type 1. J Biol Chem 281:33842–33848 32. Downes M, Carozzi AJ, Muscat GEO 1995 Constitutive expression of the orphan receptor, Rev-Erba-␣, inhibits muscle differentiation and abrogates the expression of the Myod gene family. Mol Endocrinol 9:1666–1678 33. Burke L, Downes M, Carozzi A, Giguere V, Muscat GEO 1996 Transcriptional repression by the orphan steroid receptor RVR/Rev-erb  is dependent on the signature motif and helix 5 in the E region: functional evidence for a biological role of RVR in myogenesis. Nucleic Acids Res 24:3481–3489 34. McPherron AC, Lee SJ 2002 Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 109:595–601 35. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, Kastelein JJ, Lusis AJ, Stalenhoef AFH, Stoehr JP, Hayden MR, Ntambi JM 2002 Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 43:1899–1907 36. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM, Attie AD 2002 Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99:11482–11486 37. Chawla A, Lazar MA 1993 Induction of REV-ERBA-␣, an orphan receptor encoded on the opposite strand of the ␣-thyroid hormone-receptor gene, during adipocyte differentiation. J Biol Chem 268:16265–16269 38. Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najib J, Laudet V, Staels B 1999 Fibrates increase human REV-ERB ␣ expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol 13: 400–409 39. Fontaine C, Dubois G, Duguay Y, Helledie T, Vu-Dac N, Gervois P, Soncin F, Mandrup S, Fruchart JC, FruchartNajib J, Staels B 2003 The orphan nuclear receptor
Burris • Minireview
40.
41.
42.
43.
44.
45. 46.
47.
48.
49.
50.
51.
52.
53.
54. 55.
Rev-Erb ␣ is a peroxisome proliferator-activated receptor (PPAR) ␥ target gene and promotes PPAR ␥-induced adipocyte differentiation. J Biol Chem 278:37672–37680 Canaple L, Rambaud J, Dkhissi-Benyahya O, Rayet B, Tan NS, Michalik L, Delaunay F, Wahli W, Laudet V 2006 Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor ␣ defines a novel positive feedback loop in the rodent liver circadian clock. Mol Endocrinol 20:1715–1727 Chomez P, Neveu I, Mansen A, Kiesler E, Larsson L, Vennstrom B, Arenas E 2000 Increased cell death and delayed development in the cerebellum of mice lacking the rev-erbA ␣ orphan receptor. Development 127: 1489–1498 Pircher P, Chomez P, Yu F, Vennstrom B, Larsson L 2005 Aberrant expression of myosin isoforms in skeletal muscles from mice lacking the rev-erbA ␣ orphan receptor gene. Am J Physiol Regul Integr Comp Physiol 288:R482–R490 Preitner N, Damiola F, Molina LL, Zakany J, Duboule D, Albrecht U, Schibler U 2002 The orphan nuclear receptor REV-ERB ␣ controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110:251–260 Triqueneaux G, Thenot S, Kakizawa T, Antoch MP, Safi R, Takahashi JS, Delaunay F, Laudet V 2004 The orphan receptor Rev-erb ␣ gene is a target of the circadian clock pacemaker. J Mol Endocrinol 33:585–608 Ripperger JA 2006 Mapping of binding regions for the circadian regulators bmal1 and clock within the mouse Rev-erb␣ gene. Chronobiol Int 23:135–142 Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, McNamara P, Naik KA, Fitzgerald GA, Kay SA, Hogenesch JB 2004 A functional genomics strategy reveals RORa as a component of the mammalian circadian clock. Neuron 43:527–537 Ueda HR, Chen WB, Adachi A, Wakamatsu H, Hayashi S, Takasugi T, Nagano M, Nakahama K, Suzuki Y, Sugano S, Iino M, Shigeyoshi Y, Hashimoto S 2002 A transcription factor response element for gene expression during circadian night. Nature 418:534–539 Shimba S, Ishii N, Ohta Y, Ohno T, Watabe Y, Hayashi M, Wada T, Aoyagi T, Tezuka M 2005 Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci USA 102:12071–12076 Reinking J, Lam MMS, Pardee K, Sampson HM, Liu SY, Yang P, Williams S, White W, Lajoie G, Edwards A, Krause HM 2005 The Drosophila nuclear receptor E75 contains heme and is gas responsive. Cell 122:195–207 de Rosny E, de Groot A, Jullian-Binard C, Gaillard J, Borel F, Pebay-Peyroula E, Fontecilla-Camps JC, Jouve HM 2006 Drosophila nuclear receptor E75 is a thiolate hemoprotein. Biochemistry 45:9727–9734 Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, Rastinejad F 2007 Identification of heme as the ligand for the orphan nuclear receptors REV-ERB␣ and REV-ERB. Nat Struct Mol Biol 14:1207–1213 Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, Waitt GM, Parks DJ, Pearce KH, Wisely GB, Lazar MA 2007 Rev-erb␣, a heme sensor that coordinates metabolic and circadian pathways. Science 318: 1786–1789 Woo EJ, Jeong DG, Lim MY, Jun Kim S, Kim KJ, Yoon SM, Park BC, Eon Ryu S 2007 Structural insight into the constitutive repression function of the nuclear receptor Rev-erb. J Mol Biol 373:735–744 Kaasik K, Lee CC 2004 Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. Nature 430:467–471 Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS, Hogen-
Burris • Minireview
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
esch JB 2002 Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109: 307–320 Zheng BH, Albrecht U, Kaasik K, Sage M, Lu WQ, Vaishnav S, Li Q, Sun ZS, Eichele G, Bradley A, Lee CC 2001 Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 105: 683–694 Ajioka RS, Phillips JD, Kushner JP 2006 Biosynthesis of heme in mammals. Biochim Biophys Acta Mol Cell Res 1763:723–736 Dioum EM, Rutter J, Tuckerman JR, Gonzalez G, GillesGonzalez MA, McKnight SL 2002 NPAS2: a gas-responsive transcription factor. Science 298:2385–2387 Rutter J, Reick M, Wu LC, McKnight SL 2001 Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 293:510–514 Damiola F, Le Minh N, Preitner N, Kornmann B, FleuryOlela F, Schibler U 2000 Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 14:2950–2961 Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M 2001 Entrainment of the circadian clock in the liver by feeding. Science 291:490–493 Wakamatsu H, Yoshinobu Y, Aida R, Moriya T, Akiyama M, Shibata S 2001 Restricted-feeding-induced anticipatory activity rhythm is associated with a phaseshift of the expression of mPer1 and mPer2 mRNA in the cerebral cortex and hippocampus but not in the suprachiasmatic nucleus of mice. Eur J Neurosci 13: 1190–1196 Rudic RD, McNamara P, Curtis AM, Boston RC, Panda S, Hogenesch JB, FitzGerald GA 2004 BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol 2:1893–1899 Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR, Eckel RH, Takahashi JS, Bass J 2005 Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308:1043–1045 Handschin C, Lin JD, Rhee J, Peyer AK, Chin S, Wu PH, Meyer UA, Spiegelman BM 2005 Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1 ␣. Cell 122:505–515 Lin JD, Handschin C, Spiegelman BM 2005 Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361–370 Graber SG, Woodworth RC 1986 Myoglobin expression in L6 muscle cells. Role of differentiation and heme. J Biol Chem 261:9150–9154 Holloszy JO, Winder WW 1979 Induction of ␦-aminolevulinic acid synthetase in muscle by exercise or thyroxine. Am J Physiol Regul Integr Comp Physiol 236: R180–R183 Essig DA, Kennedy JM, McNabney LA 1990 Regulation of 5⬘-aminolevulinate synthase activity in overloaded skeletal muscle. Am J Physiol Cell Physiol 259: C310–C314 Schroedl NA, Funanage VL, Bacon CR, Smith SM, Hartzell CR 1988 Hemin increases aerobic capacity of cultured regenerating skeletal myotubes. Am J Physiol Cell Physiol 255:C519–C525 Funanage VL, Schroedl NA, Moses PA, Smith SM, Kirwin JJ, Hartzell CR 1989 Hemin enhances differentiation and maturation of cultured regenerated skeletal myotubes. J Cell Physiol 141:591–597 Takahashi M, McCurdy DTM, Essig DA, Hood DA 1993 ␦-Aminolevulinate synthase expression in muscle after contractions and recovery. Biochem J 291:219–223
Mol Endocrinol, July 2008, 22(7):1509–1520 1519
73. Abraham WM, Terjung RL 1978 Increased ␦-aminolevulinic acid synthetase activity in rat ventricle after acute exercise. J Appl Physiol 44:507–511 74. Mahoney DJ, Parise G, Melov S, Safdar A, Tarnopolsky MA 2005 Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise. FASEB J 19:1498–1500 75. Wu H, Kanatous SB, Thurmond FA, Gallardo T, Isotani E, Bassel-Duby R, Williams RS 2002 Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296:349–352 76. Goto M, Terada S, Kato M, Katoh M, Yokozeki T, Tabata I, Shimokawa T 2000 cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats. Biochem Biophys Res Commun 274:350–354 77. Chen JJ, London IM 1981 Hemin enhances the differentiation of mouse 3T3-cells to adipocytes. Cell 26: 117–122 78. Ebisawa T 2007 Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes. J Pharm Sci 103:150–154 79. Hamet P, Tremblay J 2006 Genetics of the sleep-wake cycle and its disorders. Metabolism 55:S7–S12 80. Viola AU, Archer SN, James LM, Groeger JA, Lo JCY, Skene DJ, von Schantz M, Dijk DJ 2007 PER3 polymorphism predicts sleep structure and waking performance. Curr Biol 17:613–618 81. Xu Y, Toh KL, Jones CR, Shin JY, Fu YH, Ptacek LJ 2007 Modeling of a human circadian mutation yields insights into clock regulation by PER2. Cell 128:59–70 82. McClung CA 2007 Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 114: 222–232 83. Mansour HA, Monk TH, Nimgaonkar VL 2005 Circadian genes and bipolar disorder. Ann Med 37:196–205 84. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, Chakravarty S, Peevey J, Oehrlein N, Birnbaum S, Vitaterna MH, Orsulak P, Takahashi JS, Nestler EJ, Carlezon WA, McClung CA 2007 Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 104:6406–6411 85. Nievergelt CM, Kripke DF, Barrett TB, Burg E, Remick RA, Sadovnick AD, McElroy SL, Keck PE, Schork NJ, Kelsoe JR 2006 Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 141:234–241 86. Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ, Monk TH, Devlin B, Nimgaonkar VL 2006 Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav 5:150–157 87. Benedetti F, Serretti A, Mandelli L, Lorenzi C, Pirovano A, Colombo C, Smeraldi E 2003 Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Eur Neuropsychopharmacol 13:S225–S225 88. Benedetti F, Serretti A, Colombo C, Barbini B, Lorenzi C, Campori E, Smeraldi E 2003 Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet 123B:23–26 89. Serretti A, Benedetti F, Mandelli L, Lorenzi C, Pirovano A, Colombo C, Smeraldi E 2003 Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet B Nueropsychiatr Genet 121:35–38 90. Klemfuss H 1992 Rhythms and the pharmacology of lithium. Pharmacol Ther 56:53–78 91. Yin L, Wang J, Klein PS, Lazar MA 2006 Nuclear receptor Rev-erba is a critical lithium-sensitive component of the circadian clock. Science 311:1002–1005
1520 Mol Endocrinol, July 2008, 22(7):1509–1520
92. Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB 2004 Candidate genes, pathways and mechanisms for bipolar (manicdepressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry 9:1007–1029 93. Uz T, Ahmed R, Akhisaroglu M, Kurtuncu M, Imbesi M, Arslan AD, Manev H 2005 Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum. Neuroscience 134: 1309–1316 94. Lund J, Arendt J, Hampton SM, English J, Morgan LM 2001 Postprandial hormone and metabolic responses amongst shift workers in Antarctica. J Endocrinol 171: 557–564 95. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Speizer FE, Hennekens CH 1995 Prospective study of shift work and risk of coronary heart disease in women. Circulation 92:3178–3182 96. Knutsson A, Hallquist J, Reuterwall C, Theorell T, Akerstedt T 1999 Shiftwork and myocardial infarction: a case-control study. Occup Environ Med 56:46–50 97. Canaple L, Kakizawa T, Laudet V 2003 The days and nights of cancer cells. Cancer Res 63:7545–7552 98. Sahar S, Sassone-Corsi P 2007 Circadian clock and breast cancer: a molecular link. Cell Cycle 6: 1329–1331 99. Chen-Goodspeed M, Lee CC 2007 Tumor suppression and circadian function. J Biol Rhythms 22:291–298 100. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA 2001 Rotating night
Burris • Minireview
101.
102.
103.
104.
105.
106.
107.
shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568 Davis S, Mirick DK, Stevens RG 2001 Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562 Fu LN, Pelicano H, Liu JS, Huang P, Lee CC 2002 The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50 Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG 2005 Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26: 1241–1246 Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H 2003 Control mechanism of the circadian clock for timing of cell division in vivo. Science 302: 255–259 Dussault I, Giguere V 1997 Differential regulation of the N-myc proto-oncogene by ROR␣ and RVR, two orphan members of the superfamily of nuclear hormone receptors. Mol Cell Biol 17:1860–1867 Rogers PM, Ying L, Burris TP 2008 Relationship between circadian oscillations of Rev-erb␣ expression and intracellular levels of its ligand, heme. Biochem Biophys Res Commun 368:955–958 Retnakaran R, Flock G, Giguere V 1994 Identification of RVR, a novel orphan nuclear receptor that acts as a negative transcriptional regulator. Mol Endocrinol 8:1234–1244
Molecular Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.
